Prosztatarák: vizsgálatok itt: Dél-Korea
62 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisNot yet taking people in Dél-KoreaAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Goyang-si, Seoul
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - 3. fázisTaking peopleStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Where
- Seoul
- Életkor
- 18 év to 100 év
- People
- 940 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06855277 - 3. fázisTaking peopleSaruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Where
- Daegu, Goyang-si, Seoul
- Életkor
- 18 év and over
- People
- 1330 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00 - 3. fázisTaking peopleA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Where
- Busan, Daegu, Goyang-si, Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00 - 3. fázisFut, nem toborozThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Deagu, Goyang-si, Hwasun-gun, Junggu, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - 1/2. fázisNot yet taking people in Dél-KoreaPhase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
- Where
- Seoul
- Életkor
- 18 év to 99 év
- People
- 152 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07590934 - 1/2. fázisTaking peopleA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Where
- Seoul, Songpagu
- Életkor
- 18 év and over
- People
- 360 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00 - 1/2. fázisTaking peopleFirst-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
- Where
- Seoul
- Életkor
- 18 év to 100 év
- People
- 42 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07529717 - 1. fázisTaking peopleLutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 30
- Run by
- Cellbion Co., Ltd.
See details and how to joinNCT07244393 - 1/2. fázisTaking peopleStudy of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Seoul
- Életkor
- 18 év to 130 év
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 3. fázisTaking peopleA Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
- Where
- Gyeonggi-do, Seoul
- Életkor
- 18 év and over
- People
- 684 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07802704 · EU 2026-525558-13-00 - 3. fázisTaking peopleA Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer
- Where
- Gyeonggi-do, Seoul, Suwon
- Életkor
- 19 év and over
- People
- 114
- Run by
- FutureChem
See details and how to joinNCT07853209 - 1. fázisTaking peopleA Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 83 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07277270 · EU 2025-522274-37-00 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Seoul
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - 2/3. fázisTaking peopleOpen-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Where
- Seoul
- Életkor
- 18 év to 100 év
- People
- 443 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06780670 · EU 2024-512342-42-00 - 1. fázisTaking peoplePhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Seoul
- Életkor
- 18 év to 100 év
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - 2. fázisTaking peopleA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Where
- Daegu, Gwangju, Seoul
- Életkor
- 18 év and over
- People
- 218 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00 - 1/2. fázisTaking peopleA Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 52 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07192614 · EU 2025-520626-37-00 - 1/2. fázisTaking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Daegu, Goyang-si, Incheon, Seoul
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - No phaseTaking peopleProspective Study of Ultrahypofractionated Proton Beam Therapy for Localized Prostate Cancer
- Where
- Goyang-si
- Életkor
- 19 év and over
- People
- 50
- Run by
- National Cancer Center, Korea
See details and how to joinNCT07699705 - No phaseTaking peoplePost Marketing Study on Pluvicto in Korea
- Where
- Busan, Gyeonggi-do, Jeollanam, Seongnam-si, Seoul, Suwon
- Életkor
- 18 év to 100 év
- People
- 278
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06514521 - 2. fázisTaking peopleEfficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 60
- Run by
- Inkeun Park
See details and how to joinNCT06893783 - 3. fázisTaking peopleSalvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer
- Where
- Seoul
- Életkor
- 20 év and over
- People
- 270
- Run by
- Samsung Medical Center
See details and how to joinNCT07500701 - No phaseTaking peopleINSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
- Where
- Seoul
- Életkor
- 20 év and over
- People
- 1432
- Run by
- In Gab Jeong, MD
See details and how to joinNCT07398690